)
)
)
Life Biosciences
March 02, 2026
Pompeii Ballroom
Type: Innovation Stage Session
Focus Area:
Ophthalmology
Life Bio is a clinical-stage [SR3.1]biotechnology company pioneering cellular rejuvenation therapies to reverse and prevent multiple diseases of aging. The company’s proprietary Partial Epigenetic Reprogramming (PER) platform utilizes three transcription factors—Oct4, Sox2, and Klf4—to restore older and damaged cells to a younger and healthier state. This innovative approach targets a root cause of aging at the epigenetic level, thereby offering the potential to address a wide range of serious age-related diseases. Life Bio’s lead program, ER-100, is being developed for optic neuropathies, including glaucoma and non-arteritic anterior ischemic optic neuropathy (NAION), with Phase 1 initiated in the first quarter of 2026 for both indications. Beyond ER-100, the company is strategically broadening its therapeutic pipeline to address additional age-related diseases, underscoring the platform’s versatility and transformative potential.
Year Founded:
2016
Lead Product in Development:
ER-100, Phase 1 clinical trial for optic neuropathies (Glaucoma and NAION (non-arteritic anterior ischemic optic neuropathy) intiiated in 1Q26
Speakers
){kind=logo}
)
)
){kind=logo}
)
)
){kind=logo}
){kind=logo}
){kind=logo}
){kind=logo}
